Bio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & More
Xconomy
FEBRUARY 9, 2018
Second, it still hasn’t proven whether the combination helps patients more than its immunotherapy drug nivolumab (Opdivo) used alone. But the results, touted as positive, left more questions than answers. First, Bristol changed the trial’s structure midstream. More results are still to come.
58 
Let's personalize your content